巴洛沙韦：全球首次获批
Baloxavir: First Global Approval.
机构信息
Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1.
Baloxavir marboxil (Xofluza™; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.
巴洛沙韦（Xofluza™；巴洛沙韦）是罗氏（Roche）和盐野义（Shionogi）公司开发的一种口服依赖于帽子的内切酶抑制剂。该药物通过抑制 mRNA 合成的起始来阻断流感病毒的增殖。2018 年 2 月，巴洛沙韦在日本首次获得全球批准，用于治疗甲型或乙型流感病毒感染。该适应症正在美国、欧盟和其他国家进行 III 期开发。本文总结了导致甲型或乙型流感病毒感染的巴洛沙韦开发的重要里程碑，从而获得了这一全球首次批准。
Zotero 插件